Connection

Marcy Bolster to Male

Back to Details
This is a "connection" page, showing publications Marcy Bolster has written about Male.
Marcy Bolster
Connection Strength
0.271
Male
  1. Tibial stress reaction presenting as bilateral shin pain in a man taking denosumab for giant cell tumor of the bone. Bone. 2015 Dec; 81:31-35.
    View in: PubMed
    Score: 0.027
  2. Ethnic disparities among patients with pulmonary hypertension associated with systemic sclerosis. J Rheumatol. 2007 Jun; 34(6):1277-82.
    View in: PubMed
    Score: 0.015
  3. Activated Peripheral Blood B Cells in Rheumatoid Arthritis and Their Relationship to Anti-Tumor Necrosis Factor Treatment and Response: A Randomized Clinical Trial of the Effects of Anti-Tumor Necrosis Factor on B Cells. Arthritis Rheumatol. 2022 02; 74(2):200-211.
    View in: PubMed
    Score: 0.011
  4. Pulmonary Hemosiderosis with Calcification Associated with IgA Nephropathy. Am J Respir Crit Care Med. 2021 07 15; 204(2):e24-e25.
    View in: PubMed
    Score: 0.010
  5. The Association Between Physician Gender and Career Advancement Among Academic Rheumatologists in the United States. Arthritis Rheumatol. 2021 01; 73(1):168-172.
    View in: PubMed
    Score: 0.010
  6. Association of Dysregulated Central Pain Processing and Response to Disease-Modifying Antirheumatic Drug Therapy in Rheumatoid Arthritis. Arthritis Rheumatol. 2020 12; 72(12):2017-2024.
    View in: PubMed
    Score: 0.010
  7. Efficacy of Tocilizumab in Patients Hospitalized with Covid-19. N Engl J Med. 2020 12 10; 383(24):2333-2344.
    View in: PubMed
    Score: 0.010
  8. Association of Pain Centralization and Patient-Reported Pain in Active Rheumatoid Arthritis. Arthritis Care Res (Hoboken). 2020 08; 72(8):1122-1129.
    View in: PubMed
    Score: 0.010
  9. A double-blind, placebo-controlled, phase II, randomized study of lovastatin therapy in the treatment of mildly active rheumatoid arthritis. Rheumatology (Oxford). 2020 07 01; 59(7):1505-1513.
    View in: PubMed
    Score: 0.010
  10. CD4+ and CD8+ cytotoxic T lymphocytes may induce mesenchymal cell apoptosis in IgG4-related disease. J Allergy Clin Immunol. 2021 01; 147(1):368-382.
    View in: PubMed
    Score: 0.009
  11. Pain and Catastrophizing in Patients With Rheumatoid Arthritis: An Observational Cohort Study. J Clin Rheumatol. 2019 Aug; 25(5):232-236.
    View in: PubMed
    Score: 0.009
  12. Responsiveness of Patient-Reported Outcomes Measurement Information System Measures in Rheumatoid Arthritis Patients Starting or Switching a Disease-Modifying Antirheumatic Drug. Arthritis Care Res (Hoboken). 2019 04; 71(4):521-529.
    View in: PubMed
    Score: 0.009
  13. Risk Factors for Mortality and Cardiopulmonary Hospitalization in Systemic Sclerosis Patients At Risk for Pulmonary Hypertension, in the PHAROS Registry. J Rheumatol. 2019 02; 46(2):176-183.
    View in: PubMed
    Score: 0.008
  14. Core Curriculum to Facilitate the Expansion of a Rheumatology Practice to Include Nurse Practitioners and Physician Assistants. Arthritis Care Res (Hoboken). 2018 05; 70(5):672-678.
    View in: PubMed
    Score: 0.008
  15. 2015 American College of Rheumatology Workforce Study: Supply and Demand Projections of Adult Rheumatology Workforce, 2015-2030. Arthritis Care Res (Hoboken). 2018 04; 70(4):617-626.
    View in: PubMed
    Score: 0.008
  16. Association Between Pain Sensitization and Disease Activity in Patients With Rheumatoid Arthritis: A Cross-Sectional Study. Arthritis Care Res (Hoboken). 2018 02; 70(2):197-204.
    View in: PubMed
    Score: 0.008
  17. Effects of Teriparatide on Joint Erosions in Rheumatoid Arthritis: A Randomized Controlled Trial. Arthritis Rheumatol. 2017 09; 69(9):1741-1750.
    View in: PubMed
    Score: 0.008
  18. Cytokine concentrations in bronchoalveolar lavage fluid of patients with systemic sclerosis. Arthritis Rheum. 1997 Apr; 40(4):743-51.
    View in: PubMed
    Score: 0.008
  19. Utility of B-type natriuretic peptides in the assessment of patients with systemic sclerosis-associated pulmonary hypertension in the PHAROS registry. Clin Exp Rheumatol. 2017 Sep-Oct; 35 Suppl 106(4):106-113.
    View in: PubMed
    Score: 0.007
  20. Office evaluation and treatment of Raynaud's phenomenon. Cleve Clin J Med. 1995 Jan-Feb; 62(1):51-61.
    View in: PubMed
    Score: 0.007
  21. Pulmonary hypertension and interstitial lung disease within PHAROS: impact of extent of fibrosis and pulmonary physiology on cardiac haemodynamic parameters. Clin Exp Rheumatol. 2014 Nov-Dec; 32(6 Suppl 86):S-109-14.
    View in: PubMed
    Score: 0.006
  22. Eosinophilia-myalgia syndrome, toxic-oil syndrome, and diffuse fasciitis with eosinophilia. Curr Opin Rheumatol. 1994 Nov; 6(6):642-9.
    View in: PubMed
    Score: 0.006
  23. Development of pulmonary hypertension in a high-risk population with systemic sclerosis in the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS) cohort study. Semin Arthritis Rheum. 2014 Aug; 44(1):55-62.
    View in: PubMed
    Score: 0.006
  24. Survival and predictors of mortality in systemic sclerosis-associated pulmonary arterial hypertension: outcomes from the pulmonary hypertension assessment and recognition of outcomes in scleroderma registry. Arthritis Care Res (Hoboken). 2014 Mar; 66(3):489-95.
    View in: PubMed
    Score: 0.006
  25. Bisphosphonate use is associated with reduced risk of myocardial infarction in patients with rheumatoid arthritis. J Bone Miner Res. 2013 May; 28(5):984-91.
    View in: PubMed
    Score: 0.006
  26. Insufficiency fracture associated with oncogenic osteomalacia. J Clin Rheumatol. 2013 Jan; 19(1):38-42.
    View in: PubMed
    Score: 0.006
  27. Baseline characteristics and follow-up in patients with normal haemodynamics versus borderline mean pulmonary arterial pressure in systemic sclerosis: results from the PHAROS registry. Ann Rheum Dis. 2012 Aug; 71(8):1335-42.
    View in: PubMed
    Score: 0.005
  28. Bronchoalveolar lavage and response to cyclophosphamide in scleroderma interstitial lung disease. Am J Respir Crit Care Med. 2008 Jan 01; 177(1):91-8.
    View in: PubMed
    Score: 0.004
  29. Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. Am J Respir Crit Care Med. 2007 Nov 15; 176(10):1026-34.
    View in: PubMed
    Score: 0.004
  30. Scleroderma lung study (SLS): differences in the presentation and course of patients with limited versus diffuse systemic sclerosis. Ann Rheum Dis. 2007 Dec; 66(12):1641-7.
    View in: PubMed
    Score: 0.004
  31. Impact of oral cyclophosphamide on health-related quality of life in patients with active scleroderma lung disease: results from the scleroderma lung study. Arthritis Rheum. 2007 May; 56(5):1676-84.
    View in: PubMed
    Score: 0.004
  32. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med. 2006 Jun 22; 354(25):2655-66.
    View in: PubMed
    Score: 0.004
  33. Racial variation in clinical and immunological manifestations of systemic sclerosis. J Rheumatol. 2006 Feb; 33(2):263-8.
    View in: PubMed
    Score: 0.004
  34. Correlates of depression, including overall and gastrointestinal functional status, among patients with systemic sclerosis. J Rheumatol. 2005 Jan; 32(1):51-7.
    View in: PubMed
    Score: 0.003
  35. Hemodynamic effects of epoprostenol in patients with systemic sclerosis and pulmonary hypertension. Chest. 2000 Oct; 118(4):1077-82.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.